Platelet Rich Plasma application in Oral Submucous Fibrosis

Outcome Of Intralesional Application Of Platelet Rich Plasma In Cases Of Oral Submucous Fibrosis - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/05/087773

Enrollment

Registered

2025-05-28

Start date

Unknown

Completion date

Unknown

Last updated

2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H- Substance Abuse Treatment

Interventions

Intervention1: Platelet Rich Plasma: Application Of Platelet Rich Plasma In Cases Of Oral Submucous Fibrosis intralesionally Duration- 3 months Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: 1.Participants must have a confirmed diagnosis of OSMF based on clinical examination. 2.Specific age range of participants (e.g., 18-65 years) to ensure applicability and safety of PRP treatment within a certain demographic. 3.Patients at a certain clinical stage of OSMF, such as early to moderate stages, where intralesional PRP treatment is considered appropriate. 4.Willingness to undergo intralesional PRP injections and participate in follow-up assessments as required by the study protocol. 5.Participants should be in a generally stable health condition suitable for receiving PRP injections, with no active infections or other contraindications.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
1. Decrease in burning sensation of mouth according to Visual analogue scale 2.Increase in distance between upper and lower central incisorsTimepoint: At Day 0, 15, 30, 45	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Tamajit Sau

College Of Medicine and J.N.M Hospital

saumitra80@gmail.com9432815388

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026